See relevant content for Biovex.com
Total raised: $22M
Founded date: 1999
Investors 1
| Date | Name | Website |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.07.2007 | - | $22M | - |
Mentions in press and media 8
| Date | Title | Description |
| 13.05.2011 | Immunotherapy technology from Argos seeks partner for kidney cancer trials | Immunotherapy induces a patient’s own immune system to fight disease. Argo’s technology, called Arcelis, works by taking the RNA from the patient’s cancer and pairing it with the patient’s dendritic cells. Dendritic cells tell the immune sy... |
| 16.11.2009 | Ysios participa en financiación de $70M. de la norteamericana BioVex | 16/11/2009 Nota de prensa YSIOS PARTICIPA EN LA FINANCIACIÓN DE $70 MILLONES DE LA NORTEAMERICANA BIOVEX. Ysios Capital Partners, gestora española de sociedades de capital riesgo especializada en biotecnología, ha participado junto con c... |
| 10.11.2009 | BioVex Closes Raises $30M Closing $70M Financing | BioVex Inc, a Woburn, Mass.-based company developing new generation biologics for the treatment and prevention of cancer and infectious disease, has concluded a $70m private financing, raising $30m in addition to the $40m announced in March... |
| 24.07.2007 | New England’s Top 10 Q2 Venture Deals | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Yesterday we told you about the largest second-quarter venture deals in Massachusetts. Today we’re feeling more expansive, so below are the top 10 for New England. (Thanks aga... |
| 23.07.2007 | Top 10 Second-Quarter Venture Deals in Massachusetts | Share Share on Facebook Share on Twitter LinkedIn Email Reprints The second-quarter wasn’t good for Boston area venture investing, at least in overall dollar terms. The area didn’t do so well in big individual deals, either. Whereas in Q1, ... |
| 09.07.2007 | BioVex raises $22M for cancer-killing viruses | Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $22 million in a fifth funding round. Triathlon Medical Ventures led the round, joined by New Science Ventures, Forbion Capital Ventures, Aval... |
| 24.10.2006 | Medical co’s., Asthmatx and BioVex, pull IPOs — Vanguard’s rocky ride continues | Just three weeks after setting terms for its initial public offering, Mountain View medical device company Asthmatx has pulled its IPO filing. It joins Woburn, Mass. drug maker BioVex, which also pulled its IPO. They are the latest in a str... |
| - | Immunotherapy technology from Argos seeks partner for kidney cancer trials | Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from other biotechnology cancer treatments — an approach that’s completely personalized to the patient and also costs less. But that’s just the ... |